(Circulation. 1999;99:201-205.)
© 1999 American Heart Association, Inc.
Brief Rapid Communications |
Efficient and Stable Transduction of Cardiomyocytes After Intramyocardial Injection or Intracoronary Perfusion With Recombinant Adeno-Associated Virus Vectors
From the Departments of Medicine (E.C.S., D.J.M., K.W., H.L., F.J., L.C.) and Pathology (J.M.L.), University of Chicago, Chicago, Ill.
Correspondence to Jeffrey M. Leiden, MD, PhD, University of Chicago, Room B608 MC 6080, 5841 S Maryland Ave, Chicago, IL 60637. E-mail jleiden{at}medicine.bsd.uchicago.edu
Background—The delivery of recombinant genes to cardiomyocytes holds promise for the treatment of a variety of cardiovascular diseases. Previous gene transfer approaches that used direct injection of plasmid DNA or replication-defective adenovirus vectors have been limited by low transduction frequencies and transient transgene expression due to immune responses, respectively. In this report, we have tested the feasibility of using intramyocardial injection or intracoronary infusions of recombinant adeno-associated virus (rAAV) vectors to program transgene expression in murine cardiomyocytes in vivo.
Methods and Results—We constructed an rAAV containing the LacZ gene under the transcriptional control of the cytomegalovirus (CMV) promoter (AAVCMV-LacZ). We then injected 1x108 infectious units (IU) of this virus into the left ventricular myocardium of adult CD-1 mice. Control hearts were injected with the AdCMV-LacZ adenovirus vector. Hearts harvested 2, 4, and 8 weeks after AAVCMV-LacZ injection demonstrated stable ß-galactosidase (ß-gal) expression in large numbers of cardiomyocytes without evidence of myocardial inflammation or myocyte necrosis. In contrast, the AdCMV-LacZ-injected hearts displayed transient ß-gal expression, which was undetectable by 4 weeks after injection. Explanted C57BL/6 mouse hearts were also perfused via the coronary arteries with 1.5x109 IU of AAVCMV-LacZ and assayed 2, 4, and 8 weeks later for ß-gal expression. ß-Gal expression was detected in <1% of cardiomyocytes at 2 weeks after perfusion but was detected in up to 50% of cardiomyocytes 4 to 8 weeks after perfusion.
Conclusions—Direct intramyocardial injection or coronary artery perfusion with rAAV vectors can be used to program stable transgene expression in cardiomyocytes in vivo. rAAV appears to represent a useful vector for the delivery of therapeutic genes to the myocardium.
Key Words: myocardium • genes • molecular biology
This article has been cited by other articles:
 |
|
 |
|
  L. E. Vinge, P. W. Raake, and W. J. Koch Gene Therapy in Heart Failure Circ. Res., June 20, 2008; 102(12): 1458 - 1470. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Penn and A. A. Mangi Genetic Enhancement of Stem Cell Engraftment, Survival, and Efficacy Circ. Res., June 20, 2008; 102(12): 1471 - 1482. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A R Lyon, M Sato, R J Hajjar, R J Samulski, and S E Harding Gene therapy: targeting the myocardium Heart, January 1, 2008; 94(1): 89 - 99. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. J. Muller, H. A. Katus, and R. Bekeredjian Targeting the heart with gene therapy-optimized gene delivery methods Cardiovasc Res, February 1, 2007; 73(3): 453 - 462. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. I. Nykanen, K. Pajusola, R. Krebs, M. A.I. Keranen, O. Raisky, P. K. Koskinen, K. Alitalo, and K. B. Lemstrom Common Protective and Diverse Smooth Muscle Cell Effects of AAV-Mediated Angiopoietin-1 and -2 Expression in Rat Cardiac Allograft Vasculopathy Circ. Res., June 9, 2006; 98(11): 1373 - 1380. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. J. Muller, B. Leuchs, S. T. Pleger, D. Grimm, W.-M. Franz, H. A. Katus, and J. A. Kleinschmidt Improved cardiac gene transfer by transcriptional and transductional targeting of adeno-associated viral vectors Cardiovasc Res, April 1, 2006; 70(1): 70 - 78. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Chandiwal, V. Balasubramanian, Z. K. Baldwin, M. S. Conte, and L. B. Schwartz Gene Therapy for the Extension of Vein Graft Patency: A Review Vascular and Endovascular Surgery, January 1, 2005; 39(1): 1 - 14. [Abstract] [PDF]
|
|
|
|
 |
|
 J. M. Jones, J. A. Petrofski, K. H. Wilson, C. Steenbergen, W. J. Koch, and C. A. Milano {beta}2 Adrenoceptor gene therapy ameliorates left ventricular dysfunction following cardiac surgery Eur. J. Cardiothorac. Surg., December 1, 2004; 26(6): 1161 - 1168. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. G. Melo, A. S. Pachori, D. Kong, M. Gnecchi, K. Wang, R. E. Pratt, and V. J. Dzau Molecular and Cell-Based Therapies for Protection, Rescue, and Repair of Ischemic Myocardium: Reasons for Cautious Optimism Circulation, May 25, 2004; 109(20): 2386 - 2393. [Full Text] [PDF]
|
|
|
|
|
|
Y. Yue, Z. Li, S. Q. Harper, R. L. Davisson, J. S. Chamberlain, and D. Duan Microdystrophin Gene Therapy of Cardiomyopathy Restores Dystrophin-Glycoprotein Complex and Improves Sarcolemma Integrity in the Mdx Mouse Heart Circulation, September 30, 2003; 108(13): 1626 - 1632. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Chu, C. C. Sullivan, M. D. Weitzman, L. Du, P. L. Wolf, S. W. Jamieson, and P. A. Thistlethwaite Direct comparison of efficiency and stability of gene transfer into the mammalian heart using adeno-associated virus versus adenovirus vectors J. Thorac. Cardiovasc. Surg., September 1, 2003; 126(3): 671 - 679. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. R. Bridges, J. M. Burkman, R. Malekan, S. M. Konig, H. Chen, C. B. Yarnall, T. J. Gardner, A. S. Stewart, M. M. Stecker, T. Patterson, et al. Global cardiac-specific transgene expression using cardiopulmonary bypass with cardiac isolation Ann. Thorac. Surg., June 1, 2002; 73(6): 1939 - 1946. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Aikawa, G. S. Huggins, and R. O. Snyder Cardiomyocyte-specific Gene Expression Following Recombinant Adeno-associated Viral Vector Transduction J. Biol. Chem., May 17, 2002; 277(21): 18979 - 18985. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Shimpo, U. Ikeda, Y. Maeda, M. Takahashi, H. Miyashita, H. Mizukami, M. Urabe, A. Kume, T. Takizawa, M. Shibuya, et al. AAV-mediated VEGF gene transfer into skeletal muscle stimulates angiogenesis and improves blood flow in a rat hindlimb ischemia model Cardiovasc Res, March 1, 2002; 53(4): 993 - 1001. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kawada, M. Nakazawa, S. Nakauchi, K. Yamazaki, R. Shimamoto, M. Urabe, J. Nakata, C. Hemmi, F. Masui, T. Nakajima, et al. Rescue of hereditary form of dilated cardiomyopathy by rAAV-mediated somatic gene therapy: Amelioration of morphological findings, sarcolemmal permeability, cardiac performances, and the prognosis of TO-2 hamsters PNAS, January 22, 2002; 99(2): 901 - 906. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. J. Dzau, M. J. Mann, A. Ehsan, and D. P. Griese Gene therapy and genomic strategies for cardiovascular surgery: The emerging field of surgiomics J. Thorac. Cardiovasc. Surg., February 1, 2001; 121(2): 0206 - 216. [Full Text] [PDF]
|
|
|
|
|
|
H. Su, R. Lu, and Y. W. Kan Adeno-associated viral vector-mediated vascular endothelial growth factor gene transfer induces neovascular formation in ischemic heart PNAS, November 22, 2000; (2000) 250488097. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. L. Meyerson, C. L. Skelly, M. A. Curi, and L. B. Schwartz Gene Therapy for Cardiovascular Disease Seminars in Cardiothoracic and Vascular Anesthesia, November 1, 2000; 4(4): 289 - 300. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Ehsan and M. J Mann Antisense and gene therapy to prevent restenosis Vascular Medicine, May 1, 2000; 5(2): 103 - 114. [Abstract] [PDF]
|
|
|
|
 |
|
 M. RICHTER, A. IWATA, J. NYHUIS, Y. NITTA, A. D. MILLER, C. L. HALBERT, and M. D. ALLEN Adeno-associated virus vector transduction of vascular smooth muscle cells in vivo Physiol Genomics, April 27, 2000; 2(3): 117 - 127. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Hajjar, F. del Monte, T. Matsui, and A. Rosenzweig Prospects for Gene Therapy for Heart Failure Circ. Res., March 31, 2000; 86(6): 616 - 621. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Shah, R. E. Lilly, A. P. Kypson, O. Tai, J. A. Hata, A. Pippen, S. C. Silvestry, R. J. Lefkowitz, D. D. Glower, and W. J. Koch Intracoronary Adenovirus-Mediated Delivery and Overexpression of the {beta}2-Adrenergic Receptor in the Heart : Prospects for Molecular Ventricular Assistance Circulation, February 1, 2000; 101(4): 408 - 414. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Kornowski, S. Fuchs, M. B. Leon, and S. E. Epstein Delivery Strategies to Achieve Therapeutic Myocardial Angiogenesis Circulation, February 1, 2000; 101(4): 454 - 458. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. I. Miyamoto, F. del Monte, U. Schmidt, T. S. DiSalvo, Z. B. Kang, T. Matsui, J. L. Guerrero, J. K. Gwathmey, A. Rosenzweig, and R. J. Hajjar Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure PNAS, January 18, 2000; 97(2): 793 - 798. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Sinnaeve, O. Varenne, D. Collen, and S. Janssens Gene therapy in the cardiovascular system: an update Cardiovasc Res, December 1, 1999; 44(3): 498 - 506. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Su, R. Lu, and Y. W. Kan Adeno-associated viral vector-mediated vascular endothelial growth factor gene transfer induces neovascular formation in ischemic heart PNAS, December 5, 2000; 97(25): 13801 - 13806. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. C. FRANCIS, M. K. RAIZADA, A. A. MANGI, L. G. MELO, V. J. DZAU, P. R. VALE, J. M. ISNER, D. W. LOSORDO, J. CHAO, M. J. KATOVICH, et al. Genetic targeting for cardiovascular therapeutics: are we near the summit or just beginning the climb? Physiol Genomics, December 21, 2001; 7(2): 79 - 94. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. G. Melo, R. Agrawal, L. Zhang, M. Rezvani, A. A. Mangi, A. Ehsan, D. P. Griese, G. Dell'Acqua, M. J. Mann, J. Oyama, et al. Gene Therapy Strategy for Long-Term Myocardial Protection Using Adeno-Associated Virus-Mediated Delivery of Heme Oxygenase Gene Circulation, February 5, 2002; 105(5): 602 - 607. [Abstract] [Full Text] [PDF]
|
|